Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members*

Peter Hotez; Carolina Batista; Onder Ergonul; J. Peter Figueroa; Sarah Gilbert; Mayda Gursel; Mazen Hassanain; Gagandeep Kang; Jerome H. Kim; Bhavna Lall; Heidi Larson; Denise Naniche; Timothy Sheahan; Shmuel Shoham; Annelies Wilder-Smith; Nathalie Strub-Wourgaft; Prashant Yadav; Maria Elena Bottazzi

doi:10.1016/j.eclinm.2021.100780

Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members*

Peter Hotez, Carolina Batista, Onder Ergonul, J. Peter Figueroa, Sarah Gilbert, Mayda Gursel, Mazen Hassanain, Gagandeep Kang, Jerome H. Kim, Bhavna Lall, Heidi Larson, Denise Naniche, Timothy Sheahan, Shmuel Shoham, Annelies Wilder-Smith, Nathalie Strub-Wourgaft, Prashant Yadav, Maria Elena Bottazzi

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

4 Scopus citations

Original language	English (US)
Article number	100780
Journal	EClinicalMedicine
Volume	33
DOIs	https://doi.org/10.1016/j.eclinm.2021.100780
State	Published - Mar 2021

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/j.eclinm.2021.100780

Cite this

Hotez, P., Batista, C., Ergonul, O., Figueroa, J. P., Gilbert, S., Gursel, M., Hassanain, M., Kang, G., Kim, J. H., Lall, B., Larson, H., Naniche, D., Sheahan, T., Shoham, S., Wilder-Smith, A., Strub-Wourgaft, N., Yadav, P., & Bottazzi, M. E. (2021). Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members*. EClinicalMedicine, 33, [100780]. https://doi.org/10.1016/j.eclinm.2021.100780

Hotez, P, Batista, C, Ergonul, O, Figueroa, JP, Gilbert, S, Gursel, M, Hassanain, M, Kang, G, Kim, JH, Lall, B, Larson, H, Naniche, D, Sheahan, T, Shoham, S, Wilder-Smith, A, Strub-Wourgaft, N, Yadav, P & Bottazzi, ME 2021, 'Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members*', EClinicalMedicine, vol. 33, 100780. https://doi.org/10.1016/j.eclinm.2021.100780

@article{0a2f4736a2544eafa7e2ce86189f6aa4,

title = "Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members*",

author = "Peter Hotez and Carolina Batista and Onder Ergonul and Figueroa, {J. Peter} and Sarah Gilbert and Mayda Gursel and Mazen Hassanain and Gagandeep Kang and Kim, {Jerome H.} and Bhavna Lall and Heidi Larson and Denise Naniche and Timothy Sheahan and Shmuel Shoham and Annelies Wilder-Smith and Nathalie Strub-Wourgaft and Prashant Yadav and Bottazzi, {Maria Elena}",

note = "Funding Information: MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (T{\"U}BİTAK) since March 2020. JK reports personal fees from SK biosciences. JPF and GK are members of the WHO SAGE Working Group on COVID vaccines. GK is independent director of Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). SG has a patent ChAdOx1 licensed to Vaccitech, and a patent ChAdOx1 nCoV-19 licensed to AstraZeneca. SG also reports other work from Vaccitech outside the submitted work. MH is Founder and Managing Director of SaudiVax. HL reports grants and other from GSK, and grants and other from Merck, grants from J&J, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Disease, research contracts from GlaxoSmithKline, research contracts from ViiV Healthcare, and grants from Fastgrants. SS reports grants from Ansun, personal fees from Amplyx, grants from Astellas, personal fees from Acidophil, grants from Cidara, grants from F2G, personal fees from Jannssen, grants from Merck, grants from T2, personal fees from Reviral, grants from Shire, grants from Shionogi, grants from Gilead, personal fees from Intermountain Health, personal fees from Karyopharm, personal fees from Immunome, personal fees from Celltrion, outside the submitted work. NSW reports being a member of the steering committee of the COVID-19 research coalition and sponsor of a COVID-19 therapeutics trial. All other authors declare no conflict of interests. The authors views and opinions in the Commentary do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated. Funding Information: MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (T{\"U}BİTAK) since March 2020. JK reports personal fees from SK biosciences. JPF and GK are members of the WHO SAGE Working Group on COVID vaccines. GK is independent director of Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). SG has a patent ChAdOx1 licensed to Vaccitech, and a patent ChAdOx1 nCoV-19 licensed to AstraZeneca. SG also reports other work from Vaccitech outside the submitted work. MH is Founder and Managing Director of SaudiVax. HL reports grants and other from GSK, and grants and other from Merck, grants from J&J, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Disease, research contracts from GlaxoSmithKline, research contracts from ViiV Healthcare, and grants from Fastgrants. SS reports grants from Ansun, personal fees from Amplyx, grants from Astellas, personal fees from Acidophil, grants from Cidara, grants from F2G, personal fees from Jannssen, grants from Merck, grants from T2, personal fees from Reviral, grants from Shire, grants from Shionogi, grants from Gilead, personal fees from Intermountain Health, personal fees from Karyopharm, personal fees from Immunome, personal fees from Celltrion, outside the submitted work. NSW reports being a member of the steering committee of the COVID-19 research coalition and sponsor of a COVID-19 therapeutics trial. All other authors declare no conflict of interests. The authors views and opinions in the Commentary do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated.",

year = "2021",

month = mar,

doi = "10.1016/j.eclinm.2021.100780",

language = "English (US)",

volume = "33",

journal = "EClinicalMedicine",

issn = "2589-5370",

publisher = "Lancet Publishing Group",

}

TY - JOUR

T1 - Correcting COVID-19 vaccine misinformation

T2 - Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members*

AU - Hotez, Peter

AU - Batista, Carolina

AU - Ergonul, Onder

AU - Figueroa, J. Peter

AU - Gilbert, Sarah

AU - Gursel, Mayda

AU - Hassanain, Mazen

AU - Kang, Gagandeep

AU - Kim, Jerome H.

AU - Lall, Bhavna

AU - Larson, Heidi

AU - Naniche, Denise

AU - Sheahan, Timothy

AU - Shoham, Shmuel

AU - Wilder-Smith, Annelies

AU - Strub-Wourgaft, Nathalie

AU - Yadav, Prashant

AU - Bottazzi, Maria Elena

N1 - Funding Information: MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (TÜBİTAK) since March 2020. JK reports personal fees from SK biosciences. JPF and GK are members of the WHO SAGE Working Group on COVID vaccines. GK is independent director of Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). SG has a patent ChAdOx1 licensed to Vaccitech, and a patent ChAdOx1 nCoV-19 licensed to AstraZeneca. SG also reports other work from Vaccitech outside the submitted work. MH is Founder and Managing Director of SaudiVax. HL reports grants and other from GSK, and grants and other from Merck, grants from J&J, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Disease, research contracts from GlaxoSmithKline, research contracts from ViiV Healthcare, and grants from Fastgrants. SS reports grants from Ansun, personal fees from Amplyx, grants from Astellas, personal fees from Acidophil, grants from Cidara, grants from F2G, personal fees from Jannssen, grants from Merck, grants from T2, personal fees from Reviral, grants from Shire, grants from Shionogi, grants from Gilead, personal fees from Intermountain Health, personal fees from Karyopharm, personal fees from Immunome, personal fees from Celltrion, outside the submitted work. NSW reports being a member of the steering committee of the COVID-19 research coalition and sponsor of a COVID-19 therapeutics trial. All other authors declare no conflict of interests. The authors views and opinions in the Commentary do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated. Funding Information: MEB and PH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (TÜBİTAK) since March 2020. JK reports personal fees from SK biosciences. JPF and GK are members of the WHO SAGE Working Group on COVID vaccines. GK is independent director of Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). SG has a patent ChAdOx1 licensed to Vaccitech, and a patent ChAdOx1 nCoV-19 licensed to AstraZeneca. SG also reports other work from Vaccitech outside the submitted work. MH is Founder and Managing Director of SaudiVax. HL reports grants and other from GSK, and grants and other from Merck, grants from J&J, outside the submitted work. TS reports grants from National Institute of Allergy and Infectious Disease, research contracts from GlaxoSmithKline, research contracts from ViiV Healthcare, and grants from Fastgrants. SS reports grants from Ansun, personal fees from Amplyx, grants from Astellas, personal fees from Acidophil, grants from Cidara, grants from F2G, personal fees from Jannssen, grants from Merck, grants from T2, personal fees from Reviral, grants from Shire, grants from Shionogi, grants from Gilead, personal fees from Intermountain Health, personal fees from Karyopharm, personal fees from Immunome, personal fees from Celltrion, outside the submitted work. NSW reports being a member of the steering committee of the COVID-19 research coalition and sponsor of a COVID-19 therapeutics trial. All other authors declare no conflict of interests. The authors views and opinions in the Commentary do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85102105429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102105429&partnerID=8YFLogxK

U2 - 10.1016/j.eclinm.2021.100780

DO - 10.1016/j.eclinm.2021.100780

M3 - Comment/debate

C2 - 33718854

AN - SCOPUS:85102105429

SN - 2589-5370

VL - 33

JO - EClinicalMedicine

JF - EClinicalMedicine

M1 - 100780

ER -

Correcting COVID-19 vaccine misinformation: Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members*

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this